We are excited to introduce three members of our Clinical Services team: Matt Lester, RPh, MBA, Catherine Henderson, PharmD, and Celeste Zizzamia, PharmD, BCSCP. Each brings their unique expertise — including addressing business concerns, compounding for lifestyle medicine, as well as compounding for oncology patients and USP 800 minimum standards — to assist our members with questions and concerns. You will also see their respective byline in future PCCA Blog posts and Apothagram articles, as well as featured guests in future Mortar & Pestle podcasts.

ThinkNext: International Seminar 2023 (ThinkNext: ISTX23) was a huge success, attended by more than 400 global participants. We’re reviewing the pearls — highlights of key takeaways — from the event to rekindle memories and, for those who missed attending, inspire your participation next year.

Due to pending USP updates that are effective on November 1, 2023, we’re reposting our January Blog, which reviews how a modular compounding cleanroom can meet evolving regulatory requirements and standards.

Read how estrogen levels in men impact testosterone levels, the consequences of low testosterone and the potential ways compounding pharmacies can help.

Multiple studies indicate some patients with COVID-19 infection may develop vertigo. Read how betahistine helped relieve symptoms of vertigo in these post-COVID patients.

Review the criteria for selecting an FDA-approved API to safeguard your patients and your compounding pharmacy.

Read what we’re doing to ensure PCCA Formulas for compounding sterile preparations comply with USP Chapter 797 revisions.

From its humble origins as a textile dye, methylene blue has transformed into a versatile clinical agent with a wide range of potential applications.

Get flavoring tips for masking two bitter active pharmaceutical ingredients (APIs) from our flavoring expert.

Learn about the properties — including a biomarker for efficacy, known and unknown mechanisms of action and more — of minoxidil, the only FDA approved topical active pharmaceutical ingredient (API) for alopecia in men and women.